Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. Hospital of Prato意大利5
2. University of Naples Federico II意大利4
3. Istituto Neurologico Mediterraneo意大利4
4. Pfizer (Italy)意大利4
5. Ospedale Misericordia e Dolce意大利4
6. Bambino Gesù Children's Hospital意大利4
7. Azienda Ospedaliero-Universitaria Careggi意大利4
8. Inje University韩国3

按月发文

逐年被引

最新文献

1. 1
   Unraveling legionellosis dynamics in the Lazio Region: effects of individual, geographical and meteorological determinantsBMC Public Health20260
2. 2
   Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statementsExpert Opinion on Drug Safety20217
3. 3
   WSES/GAIS/SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infectionsWorld Journal of Emergency Surgery2021204
4. 4
   Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus KinasesExpert Opinion on Drug Safety202044
5. 5
   The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritisExpert Opinion on Drug Safety201911
6. 6
   Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practiceExpert Opinion on Drug Safety201964
7. 7
   2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patientsWorld Journal of Emergency Surgery2019160
8. 8
   Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variablesTherapeutics and Clinical Risk Management20184
9. 9
   Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patientsTherapeutics and Clinical Risk Management201714
10. 10
    Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysisExpert Opinion on Drug Safety201671

高被引文献

1. 1
   Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysisExpert Opinion on Drug Safety2016308
2. 2
   WSES/GAIS/SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infectionsWorld Journal of Emergency Surgery2021204
3. 3
   2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patientsWorld Journal of Emergency Surgery2019160
4. 4
   WSES guidelines for management of Clostridium difficile infection in surgical patientsWorld Journal of Emergency Surgery201592
5. 5
   Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysisExpert Opinion on Drug Safety201671
6. 6
   Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practiceExpert Opinion on Drug Safety201964
7. 7
   Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus KinasesExpert Opinion on Drug Safety202044
8. 8
   Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritisExpert Opinion on Drug Safety201623
9. 9
   Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative reviewExpert Opinion on Drug Safety201617
10. 10
    Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patientsTherapeutics and Clinical Risk Management201714

主要发表期刊